<DOC>
	<DOCNO>NCT01300793</DOCNO>
	<brief_summary>Primary objective study determine maximum tolerate dose ( MTD ) bortezomib ( Velcade ) combination rituximab , ifosfamide , carboplatin etoposide adult patient relapse refractory aggressive B-cell lymphoma . The secondary objective assess tolerability safety , response rate , rate autologous stem cell transplant CD34+ progenitor cell collection engraftment treatment regimen .</brief_summary>
	<brief_title>Study Standard-Dose Rituximab , Ifosfamide , Carboplatin Etoposide</brief_title>
	<detailed_description>Once subject determine eligible informed consent obtain , patient enrol start dose cohort 1.0mg/m2 . Based upon satisfactory safety profile , additional patient enrol 1.3 , 1.5 1.7mg/m2 cohort . Each dose cohort enrol satisfactory safety profile lower dose cohort obtain . As process continue , multiple cohort receive various dose regimen simultaneously . If DLT occur ≥2 6 patient initial dose level , 3 patient accrue dose level -1 ( 0.7mg/m2 ) . Bortezomib give day 1 ( prior rituximab ) 4 , rituximab 375 mg/m2 day 1 , carboplatin AUC 5 ifosfamide mesna , 5 gm/m2 , day 3 etoposide 100 mg/ m2/day day 2 , 3 4 21-day cycle . They also receive filgrastim day 6-13 pegfilgrastim day 6 . Dose-limiting toxicity ( DLT ) include grade 3 4 non-hematologic toxicity ( except alopecia grade 3 febrile neutropenia ) , grade 4 febrile neutropenia ( life-threatening sepsis ) grade 4 neutropenia persist past day 35 grade 3 4 thrombocytopenia persist past day 35 . If DLT give bortezomib dose level , 3 subject enrol dose ; 2 DLTs MTD define previous dose level . If dose level , &gt; 50 % subject require bortezomib dose reduction , MTD define next low dose level . Subjects continue accrue order treat minimum 10 patient MTD . Those candidate autologous stem cell transplant CT scan neck , chest , abdomen pelvis 2 cycle . Subjects PD SD take study . Those CR , PR response meeting PR criterion undergo total 3 cycle bortezomib + RICE . After 3rd cycle bortezomib + RICE , whole body PET/CT scan bone marrow biopsy obtain . Subjects achieve CR PR proceed stem cell mobilization collection standard regimen , follow autologous stem cell transplant preparative regimen determine investigator . Those SD PD take study . While mobilization ASCT procedures part phase I protocol , outcomes ASCT follow , include CD34+ progenitor cell collection , clinical response transplant survival . Subjects candidate autologous stem cell transplant CT scan neck , chest , abdomen pelvis 2nd 4th cycle . Those respond continue maximum 6 cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Aggressive Bcell nonHodgkin lymphoma , CD20 positive , first relapse refractory first secondline chemotherapy ( nonplatinum ) Diffuse large Bcell Lymphoma , Mantle Cell Lymphoma , Follicular Lymphoma ( Grade III ) , Transformed Follicular Lymphoma Prior Rituximab allow Prior radiation allow Prior autologous stem cell transplant allow Age 1870 year ECOG performance status 02 HIV seronegative No CNS involvement : CSF cytology require case bone marrow involvement , involvement 2 extranodal site , presentation testis paranasal sinus , clinical suspicion CNS involvement ( e.g. , cranial nerve deficit ) Measurable disease CT scan international work group response criterion • Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Subject platelet count less 75,000 . Subject absolute neutrophil count less 1000 Subject calculate measured creatinine clearance &lt; 60 mL/minute within 14 day enrollment . Subject grade 2 great peripheral neuropathy grade 1 pain within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Subject hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Subject treat two prior chemotherapy regimen Subject treat platinumbased regimen . Subject receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>V-RICE</keyword>
	<keyword>Relapsed NHL</keyword>
	<keyword>Primary Refractory NHL</keyword>
</DOC>